J Korean Cancer Assoc.  2000 Jun;32(3):524-530.

Combination Chemotherapy with Etoposide, Doxorubicin, Cisplatin (EAP) for Recurred or Metastatic Gastric

• Cancer Refractory to Prior Chemotherapy
• Cho NK
• Choi TS
• Park YH
• Lee SC
• Yuh YJ
• Kim SR

Abstract

PURPOSE: We performed this study to evaluate the efficacy and the safety of EAP regimen as a second line therapy for the recurred or metastatic gastric cancer unresponsive to 5-fluorouracil based chemotherapy.
MATERIALS AND METHODS
Recurred or metastatic gastric cancer patients unresponsive to 5- fluorouracil based regimen were entered into this trial. They were treated by EAP chemotherpy which consisted of etoposide 40 mg/m2, doxorubicin 15 mg/m2 and cisplatin 25 mg/m2 IV during 3 days each every 3 weeks.
RESULTS
From December 1994 to March 1998, Eighteen patients were enrolled in this protdegrees Col. Fourteen patients were evaluable for response. The overall response rate was 28.6% (95% CI: 11.7~56.7%). The median response duration was 21 weeks. The median survival for all enrolled patients was 28 weeks. The major toxicity was myelosuppression. Among total of 69 cycle che motherapy, WHO grade 3 or 4 granuldegrees Cytopenia and thrombdegrees Cytopenia were observed in 71.0% and 27.5%, respectively.
CONCLUSION
Second line therapy with EAP regimen was active for gastric cancer. Chemotherapy induced toxicities were moderate to severe.

Keyword

Stomach neoplasm; Etoposide; Doxorubicin; Cisplatin; Chemotherapy

MeSH Terms

Cisplatin*
Doxorubicin*
Drug Therapy
Drug Therapy, Combination*
Etoposide*
Fluorouracil
Humans
Stomach Neoplasms
Cisplatin
Doxorubicin
Etoposide
Fluorouracil